156 related articles for article (PubMed ID: 34602461)
1. The effects of plasma viscosity in thromboembolic events among patients with essential thrombocytosis: A case-control study.
Güney T; Can F; Alkan A; Akıncı S; Dilek İ
Clin Hemorheol Microcirc; 2022; 80(3):233-240. PubMed ID: 34602461
[TBL] [Abstract][Full Text] [Related]
2. Relevance of early diagnosis in polycythemia vera and essential thrombocythemia: A single center's experience.
Lakhwani S; Pardina-Echevarría M; Arcas-Vega R; Díaz-Sánchez OR; Hernández-García MT; Raya JM
Rev Clin Esp (Barc); 2022 Mar; 222(3):169-173. PubMed ID: 34657827
[TBL] [Abstract][Full Text] [Related]
3. Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management.
Tefferi A; Barbui T
Am J Hematol; 2017 Jan; 92(1):94-108. PubMed ID: 27991718
[TBL] [Abstract][Full Text] [Related]
4. Polycythemia vera and essential thrombocythemia: 2013 update on diagnosis, risk-stratification, and management.
Tefferi A
Am J Hematol; 2013 Jun; 88(6):507-16. PubMed ID: 23695894
[TBL] [Abstract][Full Text] [Related]
5. Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management.
Tefferi A; Barbui T
Am J Hematol; 2015 Feb; 90(2):162-73. PubMed ID: 25611051
[TBL] [Abstract][Full Text] [Related]
6. The risk of thrombosis in essential thrombocythemia and polycythemia vera.
Pearson TC
Semin Oncol; 2002 Jun; 29(3 Suppl 10):16-21. PubMed ID: 12096353
[TBL] [Abstract][Full Text] [Related]
7. Predictive Value of Kozak Gene Polymorphism for Thrombosis in Patients with Philadelphia-Negative MPNs.
El-Ghonemy MS; El-Ashwah S; Denewer M; Soliman EA; El-Baiomy M; Elkerdawy H; El-Sebaie A
Asian Pac J Cancer Prev; 2021 Apr; 22(4):1195-1201. PubMed ID: 33906312
[TBL] [Abstract][Full Text] [Related]
8. Erythrocytosis, thrombocytosis, and rate of recurrent thromboembolic event-A population based cohort study.
Larsson AE; Andréasson B; Holmberg H; Liljeholm M; Själander A
Eur J Haematol; 2023 Jun; 110(6):608-617. PubMed ID: 36725666
[TBL] [Abstract][Full Text] [Related]
9. [Essential thrombocytosis].
Van Camp G
Acta Clin Belg; 1989; 44(1):31-6. PubMed ID: 2763782
[TBL] [Abstract][Full Text] [Related]
10. Annual Clinical Updates in Hematological Malignancies: a continuing medical education series: polycythemia vera and essential thrombocythemia: 2011 update on diagnosis, risk-stratification, and management.
Tefferi A
Am J Hematol; 2011 Mar; 86(3):292-301. PubMed ID: 21351120
[TBL] [Abstract][Full Text] [Related]
11. [Essential thrombocythemia. Contribution of the V617F JAK2 mutation to the pathophysiology, diagnosis and outcome].
Brière J
Bull Acad Natl Med; 2007 Mar; 191(3):535-48. PubMed ID: 18072652
[TBL] [Abstract][Full Text] [Related]
12. Initial (latent) polycythemia vera with thrombocytosis mimicking essential thrombocythemia.
Thiele J; Kvasnicka HM; Diehl V
Acta Haematol; 2005; 113(4):213-9. PubMed ID: 15983426
[TBL] [Abstract][Full Text] [Related]
13. Polycythemia and Thrombocytosis.
Parnes A; Ravi A
Prim Care; 2016 Dec; 43(4):589-605. PubMed ID: 27866579
[TBL] [Abstract][Full Text] [Related]
14. Diagnosis, pathogenesis and treatment of the myeloproliferative disorders essential thrombocythemia, polycythemia vera and essential megakaryocytic granulocytic metaplasia and myelofibrosis.
Michiels JJ; Kutti J; Stark P; Bazzan M; Gugliotta L; Marchioli R; Griesshammer M; van Genderen PJ; Brière J; Kiladjian JJ; Barbui T; Finazzi G; Berlin NI; Pearson TC; Green AC; Fruchtmann SM; Silver RT; Hansmann E; Wehmeier A; Lengfelder E; Landolfi R; Kvasnicka HM; Hasselbalch H; Cervantes F; Thiele J
Neth J Med; 1999 Feb; 54(2):46-62. PubMed ID: 10079679
[TBL] [Abstract][Full Text] [Related]
15. Polycythemia vera and essential thrombocythemia in young patients.
Frezzato M; Ruggeri M; Castaman G; Rodeghiero F
Haematologica; 1993; 78(6 Suppl 2):11-7. PubMed ID: 8039752
[TBL] [Abstract][Full Text] [Related]
16. Thromboembolic events, major bleeding and mortality in essential thrombocythaemia and polycythaemia vera-A matched nationwide population-based study.
Enblom-Larsson A; Renlund H; Andréasson B; Holmberg H; Liljeholm M; Själander A
Br J Haematol; 2024 May; 204(5):1740-1751. PubMed ID: 38351734
[TBL] [Abstract][Full Text] [Related]
17. Limitations of fibrosis grade as diagnostic criteria for post polycythemia vera and essential thrombocytosis myelofibrosis.
Gowin K; Verstovsek S; Daver N; Pemmaraju N; Valdez R; Kosiorek H; Dueck A; Mesa R
Leuk Res; 2015 Jul; 39(7):684-8. PubMed ID: 25922307
[TBL] [Abstract][Full Text] [Related]
18. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications.
Michiels JJ; Berneman Z; Van Bockstaele D; van der Planken M; De Raeve H; Schroyens W
Semin Thromb Hemost; 2006 Apr; 32(3):174-207. PubMed ID: 16673274
[TBL] [Abstract][Full Text] [Related]
19. Long-standing thrombocytosis often precedes thromboembolic complications heralding the diagnosis of essential thrombocythemia.
Stalder G; Da Silva WR; Segot A; Blum S; Grandoni F; Alberio L
Eur J Intern Med; 2023 Jan; 107():110-112. PubMed ID: 36117085
[No Abstract] [Full Text] [Related]
20. [Thrombosis in myeloproliferative neoplasms].
Asakura H
Rinsho Ketsueki; 2018; 59(8):1034-1041. PubMed ID: 30185703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]